Methotrexate in dermatology

Dermatologic Therapy

Volumn 20, Issue 4, 2007, Pages 216-228

  Bangert, Carolyn A ^a   Costner, Melissa I ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b North Dallas Dermatology Associates   (United States)

Author keywords

Management; Methotrexate; Monitoring; Toxicity

Indexed keywords

7 HYDROXYMETHOTREXATE; ADENOSINE; ALCOHOL; AMINOTRANSFERASE; ANTIBIOTIC AGENT; CAFFEINE; CHLORAMPHENICOL; COLCHICINE; COTRIMOXAZOLE; DAPSONE; DIPYRIDAMOLE; DIURETIC AGENT; FOLIC ACID; FOLIC ACID DERIVATIVE; FOLINIC ACID; HOMOCYSTEINE; HYDROCHLOROTHIAZIDE; METHOTREXATE; METHOXSALEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PHENOTHIAZINE; PHENYTOIN; PROBENECID; RETINOID; SALICYLIC ACID; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIAMTERENE; TRIMETHOPRIM;

ADVERSE DRUG REACTION; ALGORITHM; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; APOPTOSIS; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BLISTER; BLOOD CELL COUNT; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CONGESTIVE HEART FAILURE; DERMATOLOGY; DERMATOMYOSITIS; DIARRHEA; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSPORT; DRUG URINE LEVEL; DRUG WITHDRAWAL; FATIGUE; FATTY LIVER; GASTROINTESTINAL ABSORPTION; GENETIC DAMAGE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERHOMOCYSTEINEMIA; HYPERTENSION; HYPOVOLEMIA; INFECTION RISK; KIDNEY DYSFUNCTION; KIDNEY FUNCTION TEST; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MALAISE; MEGALOBLASTIC ANEMIA; MUCOSA INFLAMMATION; NAUSEA; OLIGOSPERMIA; PANCYTOPENIA; PATIENT COUNSELING; PHOTOSENSITIVITY DISORDER; PRACTICE GUIDELINE; PREGNANCY TEST; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCREENING; SIDE EFFECT; SKIN DISEASE; SKIN INFLAMMATION; SPONTANEOUS ABORTION; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; VASCULITIS; VIRUS CARCINOGENESIS; VIRUS DETECTION;

ANIMALS; DRUG INTERACTIONS; HUMANS; LIVER; METHOTREXATE; SKIN DISEASES;

EID: 35648987727     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2007.00135.x     Document Type: Review

References (61)

1. Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006 : 58 : 473 492.
2. Hamilton RA, Kremer JM. Why intramuscular methotrexate works better than oral drug in patients with rheumatoid arthritis. Br J Rheumatol 1997 : 36 : 86 90.
3. Godfrey C, Sweeney K, Miller K, et al. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998 : 46 : 369 376.
4. Cronstein BN, Naime D, Ostad D. The anti-inflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993 : 92 : 2675 2682.
5. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005 : 57 : 163 172.
6. Oguey D, Kolliker F, Gerber NJ, Reichen J. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992 : 35 : 611 614.
7. Callen JP, Kulp-Shorten CL, Wolverton SE. Methotrexate. In : Wolverton SE, ed. Comprehensive dermatologic drug therapy, 2nd ed. Philadelphia : W.B. Saunders Co., 2007 : 147 164.
8. Roenigk HH Jr., Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988 : 19 : 145 156.
9. Roenigk HH Jr., Auerback R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis in psoriasis: consensus conference. J Am Acad Dermatol 1998 : 38 : 478 485.
10. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004 : 50 : 1370 1382.
11. El Sheikh AAK, van den Houvel JJMW, Koenderink JB, Russel FGM. Interaction of non-steroidal anti-inflammatory drugs with multidrug resistant protein (MRP) 2/ABCC2- and MRP 4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 2007 : 320 : 229 235.
12. Cronstein BN. Going with the flow: methotrexate, adenosine, and blood flow. Ann Rheum Dis 2006 : 65 : 421 422.
13. 3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res 2006 : 8 : R53.
14. Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002 : 4 : 266 273.
15. Montesinos C, Yap JS, Desai A, et al. Reversal of the anti-inflammatory effects of methotrexate by the non-selective adenosine receptor antagonists theophylline and caffeine. Arthritis Rheum 2000 : 43 : 656 663.
16. Nesher G, Mates M, Zevin S. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2003 : 48 : 571 572.
17. Nielsen CH, Albertsen L, Bendtzen K, Baslund B. Methotrexate induces poly (ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4 T cells. Clin Exp Immunol 2007 : 148 : 288 295.
18. De Lathouder S, Gerards AH, Dijkmans BA, Aarden LA. Two inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism. Nucleosides Nucleotides Nucleic Acids 2004 : 23 : 1089 1100.
19. O'Dell JR. Methotrexate, leflunomide, and combination therapies. In : Harris ED, et al., eds. Kelley's textbook of rheumatology, 7th ed. Philadelphia : Elsevier Saunders, 2005 : 900 919.
20. Marshall PS, Gertner E. Oral administration of an easily prepared solution of injectable methotrexate diluted in water: a comparison of serum concentrations vs. methotrexate tablets and clinical utility. J Rheumatol 1996 : 23 : 455 458.
21. Van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2001 : 44 : 1515 1524.
22. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990 : 33 : 9.
23. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Int Med 1994 : 121 : 833.
24. Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after the cessation of treatment. Arch Dermatol 1989 : 125 : 1218 1224.
25. Diskin CJ, Stokes TJ, Dansby LM, et al. Removal of methotrexate by peritoneal dialysis and hemodialysis in a single patient with end-stage renal disease. Am J Med Sci 2006 : 332 : 156 158.
26. Maurer TA, Zackheim HS, Tuffanelli L, Berger TG. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 1994 : 31 : 372 375.
27. Schnabel A, Gross WL. Low-dose methotrexate in rheumatic diseases - efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994 : 5 : 310 327.
28. McKendry RJR. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 1997 : 4 : 939 954.
29. Kalantzis A, Marshman Z, Falconer DT, Morgan PR, Odell EW. Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005 : 100 : 52 62.
30. Wollina K, Stander K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis - short- and long-term toxicity in 104 patients. Clin Rheumatol 2001 : 20 : 406 410.
31. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Invest 2006 : 26 : 55 62.
32. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002 : 46 : 328 346.
33. Saporito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol 2004 : 50 : 301 309.
34. Maurice PDL, Maddox AJ, Green CA, et al. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III collagen. Br J Dermatol 2005 : 152 : 451 458.
35. Chalmers RJG, Kirby B, Smith A, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate therapy: a multi-center audit and routine and health economic analysis. Br J Dermatol 2005 : 152 : 444 450.
36. Lim KY, Gaffney K, Scott DG. Methotrexate-induced pancytopenia. serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology 2005 : 44 : 1051 1055.
37. Yazici Y, Sokka T, Kautiainen H, et al. Long-term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005 : 64 : 207 211.
38. Phillips TJ, Jones TH, Baker H. Pulmonary complications following methotrexate therapy. J Am Acad Dermatol 1986 : 16 : 373 375.
39. Kamel OW, van de Rijn M, Weiss LM, et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993 : 328 : 1317 1321.
40. Moder KG, Tefferi A, Cohen MD, et al. Hematologic malignancy and the use of methotrexate in rheumatoid arthritis. A retrospective study. Am J Med 1995 : 99 : 276 281.
41. Bleyer WA. Methotrexate induced lymphoma? J Rheumatol 1998 : 25 : 404 408.
42. Kamel OW. Lymphomas during long-term methotrexate therapy. Arch Dermatol 1997 : 133 : 907 908.
43. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis. Arch Dermatol 2003 : 139 : 1425 1429.
44. Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 2006 : 142 : 1132 1135.
45. Kazlow DW, Federgrun D, Kurtin S, Lebwohl MG. Cutaneous ulceration caused by methotrexate. J Am Acad Dermatol 2003 : 49 : S197 S198.
46. Lawrence CM, Dahl CG. Two patterns of skin ulceration induced by methotrexate in patients with psoriasis. J Am Acad Dermatol 1984 : 11 : 1059 1065.
47. Pearce HP, Wilson BB. Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol 1996 : 35 : 835 838.
48. Primka EJ, 3rd. Camisa C. Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis. J Am Acad Dermatol 1997 : 36 : 815 818.
49. Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 2005 : 5 : 124 139.
50. Prodanowich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005 : 52 : 262 267.
51. Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol 1989 : 16 : 337 346.
52. Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005 : 35 : 112 121.
53. Johns TD, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972 : 112 : 978 980.
54. Morris LE, Harrod MJ, Menter MA, Silverman AK. Methotrexate and reproduction in men: case report and recommendations. J Am Acad Dermatol 1993 : 29 : 913 916.
55. Liddle BJ. Methotrexate interactions. Clin Exp Dermatol 1991 : 16 : 311 312.
56. Orr LE. Potentiation of myelosuppression from cancer chemotherapy and thiazide diuretics. Drug Intell Clin Pharm 1981 : 1 : 967 970.
57. Silke C, et al. The effects of caffeine ingestion on the efficacy of methotrexate. Rheumatology 2001 : 40 : S34.
58. Benito-Garcia E, Heller JE, Chibnik LB, et al. Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J Rheumatol 2006 : 33 : 1275 1281.
59. Wessels JAM, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with new-onset rheumatoid arthritis. Arthritis Rheum 2006 : 54 : 2830 2839.
60. Baggott BJ, Morgan SL, Sams WM, Linden J. Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol 1999 : 135 : 813 817.
61. Weisman MH, Furst DE, Park GS, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006 : 54 : 607 612.